Keith Pietropaolo

Safety and Pharmacokinetics of IDX184, a Liver-Targeted Nucleotide Polymerase Inhibitor of Hepatitis C Virus, in Healthy Subjects

Xiao‐Jian Zhou, Keith Pietropaolo, Jie Chen et al. · Antimicrobial Agents and Chemotherapy · 2010 · 63 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +12

Preclinical evaluation of AT-527, a novel guanosine nucleotide prodrug with potent, pan-genotypic activity against hepatitis C virus

Steven S. Good, Adel Moussa, Xiao‐Jian Zhou et al. · PLoS ONE · 2020 · 58 citations · Full text

Medicine, Infectious Diseases, Pharmacology +17

Safety, Pharmacokinetics, and Antiviral Activity of AT-527, a Novel Purine Nucleotide Prodrug, in Hepatitis C Virus-Infected Subjects with or without Cirrhosis

Elina Berliba, Maxim Bogus, Frédéric Vanhoutte et al. · Antimicrobial Agents and Chemotherapy · 2019 · 45 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

[6] VALOPICITABINE (NM283), ALONE OR WITH PEG-INTERFERON, COMPARED TO PEG INTERFERON/RIBAVIRIN (PEGIFN/RBV) RETREATMENT IN PATIENTS WITH HCV-1 INFECTION AND PRIOR NON-RESPONSE TO PEGIFN/RBV: ONE-YEAR RESULTS

Nezam H. Afdhal, Claire O’Brien, Eliot Godofsky et al. · Journal of Hepatology · 2007 · 41 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Single-Dose Escalation and Multiple-Dose Safety, Tolerability, and Pharmacokinetics of IDX899, a Candidate Human Immunodeficiency Virus Type 1 Nonnucleoside Reverse Transcriptase Inhibitor, in Healthy Subjects

Xiao‐Jian Zhou, Keith Pietropaolo, David Damphousse et al. · Antimicrobial Agents and Chemotherapy · 2009 · 37 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +14